C12N 2810/6081
Rhabdoviridae
Official title: rhabdoviridae, e.g. VSV
C12N2810/6081 (Rhabdoviridae) appears on 105 US grants and 204 published applications in this corpus.
Search patents in C12N- Granted patents
- 105
- Published applications
- 204
- Assignees
- 121
- Inventors
- 337
- Latest grant
- 16 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 4 | 2 |
| 2002 | 2 | 8 |
| 2003 | 0 | 13 |
| 2004 | 3 | 8 |
| 2005 | 0 | 7 |
| 2006 | 4 | 14 |
| 2007 | 5 | 7 |
| 2008 | 2 | 8 |
| 2009 | 2 | 4 |
| 2010 | 2 | 11 |
| 2011 | 1 | 5 |
| 2012 | 6 | 9 |
| 2013 | 2 | 7 |
| 2014 | 9 | 8 |
| 2015 | 6 | 13 |
| 2016 | 6 | 12 |
| 2017 | 8 | 9 |
| 2018 | 8 | 13 |
| 2019 | 7 | 7 |
| 2020 | 7 | 8 |
| 2021 | 2 | 9 |
| 2022 | 1 | 4 |
| 2023 | 7 | 3 |
| 2024 | 4 | 9 |
| 2025 | 5 | 3 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Use of microvesicles in the treatment of medical conditions16 Dec 2025US 12,497,631 B2The General Hospital Corporation
- Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM1712 Dec 2025US 12,485,187 B2Fondazione Telethon
- Retroviral transduction using poloxamers12 Aug 2025US 12,385,066 B2
- Immortalization of splenic and peripheral blood macrophages using a multi-cistronic v-raf/v-myc lentivirus22 Jul 2025US 12,365,917 B2The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- LDLR negative packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus particles thereof29 Apr 2025US 12,286,639 B2Miltenyi Biotec GmbH
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Targeting vector, preparation method therefor and use thereof21 May 2026US 2026/0137811 A1Shenzhen Genocury Biotech Co., Ltd.
- Delivery of heterologous proteins26 Feb 2026US 2026/0055146 A1Sana Biotechnology, Inc.
- Cd3-targeted lentiviral vectors and uses thereof15 May 2025US 2025/0152709 A1Sana Biotechnology, Inc.
- Viral vector and application thereof27 Mar 2025US 2025/0099586 A1Sunshine Lake Pharma Co., Ltd.
Most cited
By later US patents
- Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus184US 5,994,106 AGenVec, Inc. · 1999
- Complementary adenoviral systems and cell lines125US 5,851,806 AGenVec, Inc. · 1998
- Polynucleotide delivering complex for target cell86US 8,759,103 B2Postech Academy-Industry Foundation · 2014
- Peptide-enhanced transfections44US 8,058,068 B2Life Technologies Corporation · 2011
- Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein41US 6,338,953 B12002